Live from McKesson Accelerate 2025, host Suzzette Arnal talks with Dr. Melissa Johnson about how precision medicine is reshaping care for non-small cell lung cancer patients. They cover comprehensive biomarker testing, the role of DNA and RNA-based NGS, and why patient characteristics matter. Dr. Johnson also highlights breakthroughs in targeted therapies, emerging immunotherapies, and the critical role of clinical trials in improving outcomes.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.